GSK announces that the Japanese Ministry of Health, Labor and Welfare has approved Omjjara (momelotinib) for the treatment of myelofibrosis.

This approval is based on two Phase III trials. The company points out that this is the fourth major approval for this drug, following approvals in the United States, Europe and the United Kingdom.

Omjjara's approval thus offers a new treatment option for Japanese patients.

As a reminder, myelofibrosis affects around 1 in 500,000 people worldwide, with up to 5,000 patients in Japan, many of whom develop anemia requiring transfusions.


Copyright (c) 2024 CercleFinance.com. All rights reserved.